Screener
Krystal Biotech, Inc. KRYS Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Depreciation | 1,522 | 1,410 |
| Accretion on marketable securities | (576) | (453) |
| Amortization of operating lease right-of-use assets | 204 | 224 |
| Stock-based compensation expense, net | 13,609 | 13,478 |
| Realized gain on investments | (529) | (1,502) |
| Other, net | 136 | 614 |
| Changes in operating assets and liabilities | ||
| Accounts receivable, net | 58 | 1,486 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s stock-based comp?
- Krystal Biotech, Inc. (KRYS) reported stock-based comp of $13.61M in Q1 2026.
- How has Krystal Biotech, Inc.'s stock-based comp changed year-over-year?
- Krystal Biotech, Inc.'s stock-based comp increased by 1.0% year-over-year, from $13.48M to $13.61M.
- What is the long-term trend for Krystal Biotech, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s stock-based comp has grown at a 37.3% compound annual growth rate (CAGR), from $15.32M to $54.51M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Krystal Biotech, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude